1 of 1
Story summary
- A study from the Hebrew University of Jerusalem finds cannabidiol (CBD) and cannabigerol (CBG) may help treat metabolic dysfunction-associated steatotic liver disease (MASLD) by lowering liver fat.
- MASLD affects about one-third of adults globally, according to the study.
- The researchers note these effects are not yet confirmed in humans and require trials.
- A separate review highlights gaps in evidence for cannabis and notes cannabinoid therapies are not universally effective.
